We all know someone suffering from Long COVID. And, if you’re like me, you’ve been waiting patiently for results of the Harvard/MGH Long COVID clinical study (Details) evaluating NAD+ boosting supplement Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes) as a possible treatment. So, what’s the status of the study? Chromadex CEO Rob Fried explained during an investor presentation at the end of August:
Category: COVID-19 Page 1 of 2
From yesterday’s Chromadex (sellers of Nicotinamide Riboside “NR” (FAQs) (Reviews)) earnings call:
During an ongoing Reddit AMA (Ask Me Anything), NAD+ expert Dr. Charles Brenner (FAQs) was asked repeatedly to make the case for taking NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes). Again, keep in mind that Dr. Brenner takes NR daily. Here’s the Redditors’ questions followed by Brenner’s responses:
On July 21st, Science published a paper entitled “What is really known about the effects of nicotinamide riboside supplementation in humans“. Below is the authors’ conclusion followed by reaction from Dr. Charles Brenner (FAQs) who discovered Nicotinamide Riboside “NR” (FAQs) (Anecdotes) as an NAD+ precursor vitamin:
An article this past weekend in the Toronto Sun claims that “Brain fog”, a typical symptom of long COVID, is currently a major concern for both scientists and sufferers alike. One possible treatment being tested is NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes). Key quote:
For some time, we’ve been tracking the Harvard/MGH clinical study currently assessing the efficacy of vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) in alleviating some of the symptoms associated with “long haul COVID”. In a presentation this past week entitled “A Randomized Placebo Controlled Parallel Group Clinical Trial testing the impact of Nicotinamide Riboside (NR) on NAD+ Levels and Long COVID symptom recovery: Preliminary Baseline Findings“, Harvard’s Dr. Edmarie Guzmán-Vélez shared some of her preliminary findings. We encourage you to watch the presentation in its entirety (video embedded below). If you don’t have time, here are some key quotes:
What can be done to help COVID-19 long haulers? Well, some scientists believe that NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) could be a treatment solution. One of those scientists is Harvard Alzheimer’s expert Dr. Rudy Tanzi. And he recently initiated a human clinical trial to see if he’s correct (UPDATE: Results expected soon). Here are some key quotes regarding the clinical trial:
Many companies have come forward over the last 2 years claiming they have treatments for COVID. And most of those claims have turned out to be nonsense. On the flip side, some companies have products that have been shown in human studies to be effective against COVID, and yet they’re prevented from informing the general public by restrictions imposed by regulatory bodies. One of those products appears to be NAD boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews):
During a media interview late last week, UFC boss Dana White talked about his fast recovery from COVID. He attributed his recovery to a treatment plan recommended by his friend and prominent podcaster Joe Rogan that included an NAD IV drip. Below is Dana White’s video interview:
On one of his first podcasts since recovering from COVID (an NAD IV drip was part of his treatment), Joe Rogan discussed his recovery and what he’s hearing from fellow NAD IV (FAQs) enthusiasts:
After contracting COVID, outspoken podcaster Joe Rogan fought back with a treatment plan that included NAD IV drips (FAQs). For some (but not all), NAD drips are a preferred alternative to NAD boosting supplements Nicotinamide Riboside “NR” (FAQs) (Reviews) and NMN (FAQs). Below is Rogan’s Instagram video where he provides more detail:
At the end of June, results from a Phase 3 clinical trial were published showing that a cocktail of metabolic activators including Nicotinamide Riboside “NR” (FAQs) (Reviews) significantly reduced recovery time in mild to moderate COVID-19 patients. Previously, in response to Phase 2 results, Dr. Charles Brenner (who discovered NR as an NAD precursor vitamin) commented on Twitter: “I expect NR was driver of the beneficial effects in ppl“. And now that the full Phase 3 study results have finally been published, Dr Brenner said the following on a mid-July podcast (video embedded below):
We know that many people are experiencing long haul COVID symptoms. As a result, scientists are looking for possible treatments. One of those scientists is Harvard professor and Alzheimer’s expert Dr. Rudy Tanzi who in partnership with Massachusetts General Hospital recently launched a clinical study looking at Nicotinamide Riboside “NR” (FAQs) (Reviews). Should COVID long haulers be optimistic about Dr Tanzi’s human NR study? Chromadex CEO Rob Fried weighed in on this very issue at the Benzinga Small-Cap Conference yesterday:
For most of us, NAD is a foreign concept. But, according to top scientists, it’s critical to human health. Why does NAD remain under the radar? Because it’s not a simple concept. It’s not easily accessible. So, when we at RaisingNAD find an interview or video which explains NAD in plain simple English we jump at the opportunity to share it. The following is an example from last week:
In numerous recent interviews (Here and Here), top Harvard Alzheimer’s expert Dr Rudy Tanzi discussed plans to initiate 2 human clinical studies using NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews). In one study, Dr Tanzi will focus on Alzheimer’s patients. And in the other, which was posted on ClinicalTrials.gov earlier this week Dr Tanzi will focus on long-haul COVID patients experiencing persistent cognitive and physical symptoms. You may remember that Dr Tanzi knows a lot about NR through both personal supplementation (“I religiously take Tru Niagen“) AND his association with the NFL’s New England Patriots. As a result, many have been eagerly awaiting these two clinical trials. Here’s more on the COVID trial posted earlier this week:
We know that there’s enormous interest in studying Nicotinamide Riboside “NR” (FAQs) (Reviews) in the science community. A quick look at the 50+ ongoing or completed clinical trials says it all. But who are these scientists? Chromadex CEO Rob Fried talked about some of them at the Oppenheimer Health Care Conference yesterday.
As a public company, Chromadex has few opportunities each year to talk openly with the public about Nicotinamide Riboside “NR” (FAQs) (Reviews). Last evening was one of those times. The following are key quotes from Chromadex CEO Rob Fried and Chairman Frank Jaksch during management’s Q4 2020 earnings call.
In advance of this week’s earnings call, Wall Street analysts at B Riley published a note today on Chromadex and recent developments relating to Nicotinamide Riboside “NR” (FAQs) (Reviews). The following are key excerpts.
Last week, a new Phase 3 human clinical study conducted in Turkey demonstrated that patients with mild-to-moderate COVID-19 who received the standard of care experienced a 3.5 day reduction in recovery time when receiving a nutritional protocol. The nutritional protocol included Nicotinamide Riboside “NR” (FAQs) (Reviews). These Phase 3 results follow Phase 2 data which were published in October 2020. Below are Dr Charles Brenner’s (who discovered NR as an NAD precursor vitamin) evaluation of the two studies and his opinion on the role of NR.
We’ve heard some incredible stories here from consumers impacted by supplementing with Nicotinamide Riboside “NR” (FAQs) (Reviews). Who can forget Mark’s story about his successful battle with epilepsy? What about Shelly overcoming RLS? The anecdotal evidence appears endless. Now comes a story from Dennis Smith. Kudos to him for sharing his very personal story (please consider sharing your own NAD+ supplement experience below):
In a video podcast interview last week, City of Hope’s Dr. Charles Brenner — who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin — fielded a host of questions from a New Zealand trained MD. While there’s lots of science here, there’s also lots of accessible information. The following are 4 key takeaways (video interview embedded below).
Chromadex CEO Rob Fried joined The Big Biz Show for the second time in a month to discuss Nicotinamide Riboside “NR” (FAQs) (Reviews), COVID studies, and frequently asked questions from NR consumers. Key quotes:
Chromadex CEO Rob Fried joined The Morning Show with Ken Lanphear late last week. As with every media interview he’s involved in, we learned a bit more about Nicotinamide Riboside‘s “NR” (FAQs) (Reviews) possible impact on COVID-19 patients. And while he’s encouraged by progress toward treatments for those infected with COVID-19, he’s concerned about progress toward a vaccine. The following are key quotes:
Chromadex CEO Rob Fried joined the “Mottek on Money” radio show yesterday. His concluding message on flagship product Nicotinamide Riboside “NR” (FAQs) (Reviews): “…the growth has been fairly dramatic and we expect it to continue as more people become aware of how taking this thing can impact your health, help you to heal, help you to grow, help you to have more energy, and essentially help you to age.” The following are other key quotes (link to podcast below).
INTERVIEW: Chromadex CEO on Multiple Studies Showing Nicotinamide Riboside (NR) Helps Fight COVID-19
Chromadex CEO Rob Fried joined the Big Biz Radio Show last week. The following are key quotes about NAD boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews):
Harvard’s David Sinclair and City of Hope’s Charles Brenner often talk about NAD boosters as potential help for those fighting COVID-19. A new Phase-2 clinical study suggests they may be correct. The study focused on patients with mild-to-moderate COVID-19 symptoms who received the standard of care in combination with a nutritional protocol including Nicotinamide Riboside “NR” (FAQs) (Reviews). Below is a concise explanation of the study – and, more important, NAD expert Dr Brenner’s take on the findings (see the last line).
This week’s New York Times Magazine suggests that “many Covid-19 patients may be dying from their immune response to the virus, NOT from the virus itself.” COVID-19 patients’ immune overreaction is known as a “Cytokine Storm”. What’s the NAD connection? Harvard’s David Sinclair and City of Hope’s Charles Brenner agree — “cytokine storms” are the result of depleted NAD. And thus it’s plausible that NAD boosters could help.
The Daily Buzz has a short interview with NAD expert Dr. Charles Brenner discussing his research into COVID-19 and NAD. Key quotes and video embedded below.
Horizons Ventures is the private investment arm of Hong Kong billionaire Li Ka-shing. They were early investors in many successful companies including Facebook and Spotify. They’re also a top shareholder of NAD booster company Chromadex. Notice they promote Chromadex at the top of their homepage under the menu heading “Fight COVID-19“.
Last week, Chromadex (Nicotinamide Riboside “NR” (FAQs) (Reviews)) reported earnings results. On management’s earnings call CEO Rob Fried said the following:
Dr. Charles Brenner, discoverer of Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin joined yet another local TV station to share his findings about the potential connection between NAD and COVID-19. This time he joined WJAX. Key article excerpt and video embedded below.
Harvard Genetics Professor David Sinclair PhD, author of Lifespan, joined Kahn Academy last week to talk NAD and much more. Sinclair excels at discussing NAD, longevity, and science in easily accessible ways. The following are key quotes from his 40 minute interview with Sal Kahn (video embedded below):
Dr Charles Brenner (FAQs), who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD precursor vitamin and is actively studying NR’s impact on the treatment of COVID-19 joined WTKR CBS TV 3 last week to discuss his latest research. Key quotes below:
Dr. Charles Brenner (FAQs), who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin and is actively studying NR’s impact on the treatment of COVID-19 recently joined YOU The Owner’s Manual Podcast (Host Dr. Michael Roizen is Chief Wellness Officer at Cleveland Clinic) to discuss his latest research. Key quotes and podcast embedded below:
Chromadex CEO Rob Fried appeared on a UK radio show last week to promote the UK retail launch of Nicotinamide Riboside “NR” (FAQs) (Reviews) and discuss NAD, NR, and COVID-19. Key quotes and video embedded:
Dr. Charles Brenner, who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin and is actively studying NR’s impact on the treatment of COVID-19 recently joined PRECISIONE: The Healthcast podcast to discuss his latest research. Key quotes and podcast embedded below:
Dr Charles Brenner, who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin and is actively studying NR’s impact on the treatment of COVID-19 joined WSAW CBS TV 7 late last week to discuss his latest research. The 3 minute interview was similar to one earlier in the week. Key quotes:
Dr Charles Brenner, who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin and is actively studying NR’s impact on the treatment of COVID-19 joined WRAL NBC TV 5 today to discuss his latest findings. Read or watch below:
Chromadex reported Q1 2020 earnings results earlier this week. The following are key quotes from management’s earnings call discussing COVID-19 decimating NAD levels and Nicotinamide Riboside “NR” (FAQs) (Reviews) as a possible solution:
Chromadex reported Q1 2020 earnings results yesterday. The following are key quotes from management’s earnings call relating to NAD+, Nicotinamide Riboside “NR” (FAQs) (Reviews), and COVID-19:
In a wide ranging Twitter Q&A yesterday, Dr. Charles Brenner, who discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin and is actively studying NR’s impact on the treatment of COVID-19 said the following:
Dr. Charles Brenner, University of Iowa professor and chief scientific advisor at Chromadex took questions from the public on Twitter today. He discovered Nicotinamide Riboside “NR” (FAQs) (Reviews) as an NAD boosting vitamin. Here’s the Q&A: